Key result
The efficacy of nifekalant and radiofrequency catheter ablation was described for refractory neonatal congenital junctional ectopic tachycardia.
Why the study?
Does nifekalant and radiofrequency catheter ablation improve outcomes in infants with refractory neonatal congenital junctional ectopic tachycardia?
Case Report
Does nifekalant and radiofrequency catheter ablation improve outcomes in infants with refractory neonatal congenital junctional ectopic tachycardia?
The paper discusses the potential efficacy of nifekalant and catheter ablation for refractory neonatal congenital junctional ectopic tachycardia, while highlighting the risk of atrioventricular conduction damage.
Answers are grounded in this paper and cite their sources.
May warrant consideration in refractory neonatal congenital junctional ectopic tachycardia; leaves open need for controlled trials on efficacy and conduction safety.
Congenital junctional ectopic tachycardia (JET) is a rare idiopathic disorder that presents during infancy. It is caused by abnormal automaticity near the atrioventricular (AV) node or proximal His bundle.1 Although the survival rate has improved because of progress in medical treatment and catheter ablation (CA), JET is still associated with a high morbidity and mortality.2–4 There are some reports about the efficacy of medications such as amiodarone (AMD)2–4 and CA, but no reliable treatment has been established thus far.
No takes yet. Share an insight, caveat, or question.
Aoki et al. (2017) conducted a case report in Refractory neonatal congenital junctional ectopic tachycardia. Nifekalant and radiofrequency catheter ablation was evaluated. The efficacy of nifekalant and radiofrequency catheter ablation was described for refractory neonatal congenital junctional ectopic tachycardia.
Synapse has enriched 10 related papers. Consider them for comparative context: